Life Expectancy Assessments in Life Settlements

What a Life Expectancy Assessment Actually Is

In the life settlement context, a life expectancy (LE) assessment is a professional medical-actuarial opinion, delivered as a written report, estimating the probable remaining lifespan of the insured person. It is produced by an independent underwriting firm — not by the buyer, not by the seller’s doctor, and not by the insurance carrier that issued the policy.

The report typically contains:

• A median life expectancy in months — the point at which 50% of similar individuals would have passed away;
• A mortality multiplier expressing how the insured’s expected mortality compares to a standard population (for example, 250% of standard);
• A survival curve or mortality table extract showing month-by-month survival probabilities, which is what pricing models actually consume;
• A summary of the medical conditions and factors driving the estimate.

It is important to understand what the assessment is not. It is not a prediction about an individual — no one can know when a specific person will pass away. It is a statistical statement: among many people with this profile, half would be expected to survive past the median. Buyers can rely on such statistics because they hold pools of policies, as explained in how life settlement investors make money.

The assessment is also entirely non-invasive. The insured is never examined, tested, or interviewed by the underwriting firm. Everything is derived from existing medical records, prescription histories, and attending physician statements gathered during the application phase of the life settlement process.

Who Performs the Assessment — and Why Independence Matters

LE assessments are produced by a small industry of specialized medical underwriting firms whose entire business is estimating longevity for the secondary insurance market. Their staff combine physicians, nurses, and actuaries; their product is credibility.

Independence is the load-bearing feature of the system. Consider the incentives if it were otherwise: a buyer producing its own LE estimates could stretch them longer to justify lower offers; a seller commissioning its own could shade them shorter to demand higher prices. Neither report would be worth the paper. Independent firms, paid flat fees regardless of the transaction outcome, and dependent on long-run accuracy for their reputations, break that conflict.

Market practice adds a second safeguard: buyers customarily order two reports from different firms, and some order three for large policies. Firms use different proprietary methodologies and can disagree meaningfully on the same records; using multiple opinions dampens any single firm’s bias or blind spot. The full logic of the two-report convention is the subject of independent life expectancy reports: why two are ordered.

Regulators reinforce the structure. Several states license or register life expectancy providers, and the consumer-protection framework that grew out of the NAIC Life Settlements Model Act contemplates accurate, non-fraudulent underwriting as a foundation of fair transactions. The GAO’s study of the market likewise flagged life expectancy estimation as central to both investor outcomes and consumer pricing — the estimate is, in a real sense, the price.

Inside the Underwriting Process: Debits, Credits, and Tables

Once the underwriting firm receives the medical file, the assessment proceeds in recognizable stages.

1. Record assembly and review. Nurses and physicians read attending physician statements, hospital records, lab results, imaging reports, and prescription histories — typically covering the last several years. They build a clinical picture: diagnoses, severity, progression, treatment response, and functional status (mobility, independence, cognition).

2. Condition scoring — debits and credits. The firm starts from a baseline mortality table for the insured’s age and sex, then applies debits (factors increasing expected mortality: heart failure, COPD, cancer history, renal disease, frailty markers) and credits (factors decreasing it: excellent functional status, strong treatment response, favorable family longevity, well-controlled conditions). The net score becomes a mortality multiplier.

3. Table application. The multiplier is applied to the base table to generate the survival curve and the median LE in months.

4. Peer review and issuance. Senior underwriters or medical directors review non-routine cases before the report is released.

A few realities of the craft deserve emphasis. Comorbidity interactions are hard: diabetes plus cardiac disease is worse than either alone, and firms model these interactions differently — one source of divergence between reports. Recency matters: a two-year-old cardiology workup will be treated more conservatively than a current one. And documentation gaps default against the insured’s impairments being credited — an undocumented condition is, for underwriting purposes, a condition that does not exist. That last point is why sellers should treat record-gathering as economic work, not paperwork, as discussed in who qualifies for a life settlement.

How the Estimate Translates into Dollars

The LE report is not commentary on the offer — it substantially is the offer. Buyers feed the survival curve directly into a discounted cash flow model alongside the policy’s premium schedule and their required return, as detailed in life settlement pricing mechanics.

The mechanism runs through both sides of the ledger:

• Premium side: a longer LE means more years of premiums the buyer must fund, each of which subtracts from what they can pay today. On universal life policies, later-year premiums are also larger, compounding the effect.
• Benefit side: a longer LE pushes the death benefit further into the future, where discounting shrinks its present value year by year.

Both effects point the same direction, which is why price sensitivity to LE is so steep. As a stylized illustration: moving a median estimate from 84 months to 108 months on a sizable universal life policy can cut the modeled value by a third or more. Across the market, this machinery produces the familiar outcome ranges — settlements typically paying 10-35% of face value and roughly 4-8 times cash surrender value, with short-LE cases at the top of the range and long-LE cases at the bottom or priced out entirely.

The translation also explains a counterintuitive experience many sellers report: good medical news can mean a lower offer, and serious diagnoses can raise one. The market is pricing the policy as an asset, not evaluating the person. Sellers uncomfortable with that framing — a reasonable reaction — should weigh it explicitly when comparing a settlement against alternatives like those in life settlement vs. surrender.

Assessment Factor	Examples	Typical Effect on Estimated Life Expectancy	Effect on Offer
Major impairments (debits)	Congestive heart failure, COPD, metastatic cancer history, renal disease	Shortens estimate via higher mortality multiplier	Raises modeled value, all else equal
Protective factors (credits)	Strong functional status, well-controlled conditions, family longevity	Lengthens estimate	Lowers modeled value
Comorbidity interactions	Diabetes plus cardiac disease; frailty plus cognitive decline	Compounding effect beyond individual conditions	Often the difference between report firms
Documentation quality	Current specialist notes vs. multi-year-old records	Gaps default to healthier (longer) assumptions	Incomplete files systematically depress offers
Age and sex baseline	Base mortality table before adjustments	Older baseline = shorter starting expectancy	Why marketability generally begins around age 65+

The Timeline: Where the Assessment Sits in Your 60-120 Days

Life expectancy underwriting is one of the two long poles in the settlement timeline (the other being medical record retrieval itself). A typical sequencing within the overall 60-120 day process:

• Weeks 1-4: authorization and record gathering. The seller signs HIPAA releases; a retrieval service requests records from every physician, hospital, and pharmacy identified. Slow provider offices are the most common cause of delay in the entire transaction.
• Weeks 4-8: LE reports in production. The assembled file goes to two independent underwriting firms, each taking roughly 2-6 weeks depending on case complexity and workload. The reports are usually ordered in parallel, not sequentially.
• Weeks 6-10: pricing and bidding. With reports in hand, buyers run their models and submit bids; in a brokered process, multiple bidding rounds occur.
• Weeks 10-17: contracts, escrow, carrier change forms, and funding — followed by the state-mandated rescission window of 15-30 days after closing.

Sellers can compress the front end meaningfully: providing a complete physician list with accurate contact details, signing authorizations promptly, and nudging slow medical offices can save weeks. The back end is largely fixed by underwriting firm turnaround and state procedure.

One timing nuance: LE reports have shelf lives. Buyers generally consider a report stale after roughly a year — sometimes sooner if health has changed — so a seller who pauses mid-process for many months may need refreshed underwriting. The full transaction chronology is mapped in how life settlements work.

Privacy, Consent, and Who Sees Your Medical File

Understandably, many policyholders hesitate at the idea of strangers reading their medical history. The system’s answer is consent-gated, purpose-limited access under multiple layers of law.

Nothing moves without the insured’s signed authorization — a HIPAA-compliant release specifying who may obtain records and for what purpose. From there, access is confined to the working chain: the record-retrieval service, the independent underwriting firms, the licensed provider, and the funds evaluating the purchase. State life settlement statutes modeled on the NAIC framework add industry-specific confidentiality duties: medical and personal information may be used only for effecting the settlement, may not be sold or shared for unrelated purposes, and post-closing contact with the insured for status verification is limited in frequency and manner.

Practical points sellers should know:

• Authorizations are revocable. A seller who withdraws from the process can revoke releases going forward.
• Reports identify, but circulate narrowly. LE reports travel with the case file to bidding buyers under confidentiality obligations; they are not public documents.
• The carrier is not underwriting you again. The issuing insurance company does not receive the LE reports and cannot use the settlement process to re-rate or contest a validly issued policy outside contestability rules.
• After closing, the servicing company’s periodic status checks are administrative, bounded by statute, and handled by professionals — a point that also answers a common myth addressed in who buys life insurance policies.

Sellers who want extra assurance can ask any broker or provider to walk through, in writing, exactly which entities will receive the file — a request legitimate market participants handle routinely.

Why Estimates Differ — and What History Taught the Industry

Two competent firms reading the same file can and do issue different estimates — sometimes differing by a year or more. Understanding why makes the system less mysterious.

• Methodology: firms maintain proprietary base tables, debit-credit schedules, and comorbidity models built from their own experience data;
• Interpretation: clinical judgment on severity and progression varies, especially for conditions with uncertain trajectories such as early-stage cancers or dementia;
• Data emphasis: one firm may weight functional status heavily, another lab trends;
• Table vintage: firms update mortality tables on different schedules as population longevity improves.

History supplies a cautionary tale. In 2008, leading underwriting firms lengthened their LE methodologies significantly after actual survival in insured pools exceeded prior estimates. Portfolios priced on the older, shorter estimates underperformed, litigation followed, and buyers learned to treat any single estimate with humility — a chapter recounted in the GAO report and in our history of life settlements. The episode entrenched today’s practices: multiple independent reports, conservative blending, actual-to-expected tracking of firm accuracy, and periodic re-underwriting of held portfolios.

For sellers, divergent reports are not a defect to fear but a feature to understand: the buyer’s choice of how to combine them (average, worst-case, or weighted) is a pricing assumption you are entitled to ask about, as suggested in the due-diligence questions in how life settlement value is calculated.

Preparing for Your Assessment: A Seller’s Checklist

The seller cannot — and should not — influence the medical conclusions, but can materially improve the process’s speed and the estimate’s accuracy. Accuracy is the goal: an estimate built on complete information is the estimate most likely to credit real impairments and produce a fair price.

• Build a complete provider list. Every physician, specialist, hospital, and clinic seen in the last five years, with addresses and phone numbers. Missing specialists are missing debits.
• Include the pharmacy history. Prescription databases corroborate diagnoses and adherence; list all pharmacies used.
• Get current where it counts. If a major condition hasn’t been evaluated recently, a current attending physician statement can replace conservative assumptions with documented reality. (See a doctor for health reasons, not settlement reasons — but do forward recent results.)
• Never exaggerate or conceal. Misrepresentation in either direction is fraud under state life settlement acts, can void the transaction, and destroys the file’s credibility. The system descends from Grigsby v. Russell‘s property principle, but its integrity rests on truthful underwriting.
• Sign and return authorizations promptly. Weeks die in unsigned-release purgatory.
• Plan for taxes in parallel. While underwriting runs, review the IRS three-tier treatment under Rev. Rul. 2009-13 with a tax professional — see the tax treatment guide — so the net number is ready when offers arrive.

Treat the assessment as the pricing engine it is, and the rest of the transaction becomes far easier to navigate.

---

Frequently Asked Questions

What is a life expectancy report in a life settlement and who prepares it?

It is a written medical-actuarial opinion estimating how long the insured is likely to live, prepared by an independent underwriting firm that specializes in longevity analysis for the secondary insurance market. The report includes a median life expectancy in months, a mortality multiplier relative to standard tables, and a survival curve used directly in pricing models. Neither the buyer nor the seller prepares it; independence is the point, and buyers customarily order two reports from separate firms to offset methodological differences.

Do I need a medical exam to get a life expectancy assessment for a life settlement?

No. The assessment is entirely records-based. After you sign HIPAA-compliant authorizations, a retrieval service collects your medical records, prescription history, and attending physician statements, and the underwriting firms work solely from that file. There are no exams, blood draws, or interviews. This is one way life settlement underwriting differs from buying insurance in the first place. The practical implication is that your written records are everything: conditions that are not documented cannot be credited, so completeness directly affects the estimate and the offer.

How long does the life expectancy assessment take in the settlement process?

The underwriting itself typically takes about 2-6 weeks per report once the medical file is complete, and buyers usually order the two reports in parallel. The slower stage is often assembling the records beforehand, which can take several weeks depending on how quickly physician offices respond. Within the overall 60-120 day life settlement timeline, record gathering plus life expectancy underwriting usually consumes the first half. Sellers can shorten it by providing a complete provider list and returning authorizations immediately.

Why does a shorter life expectancy mean a higher life settlement offer?

Because the buyer’s economics improve on both sides of the ledger. A shorter estimate means fewer years of premium payments the buyer must fund and a death benefit that arrives sooner, which discounts to a higher present value. Both effects raise the maximum price the buyer’s model can justify. This is also why offers cluster in the typical 10-35% of face value range: insureds with significant impairments price near the top, while healthier insureds price near the bottom or receive no offers at all.

Can two life expectancy reports on the same person really be different?

Yes, and meaningfully so — differences of a year or more are not unusual. Firms maintain proprietary mortality tables, debit-credit schedules, and comorbidity models, and clinicians can weigh the same chart differently, especially for conditions with uncertain trajectories. This is precisely why the market convention is two independent reports: using multiple opinions dampens any single firm’s bias. Buyers then blend the estimates or use the more conservative one, and sellers are entitled to ask how the reports were combined in the bid they received.

Who sees my medical records during a life settlement, and is it legal?

Access is consent-based and purpose-limited. Your signed HIPAA authorization permits the retrieval service, the independent underwriting firms, the licensed provider, and evaluating buyers to use the records solely to underwrite and complete the settlement. State life settlement statutes modeled on the NAIC framework add confidentiality duties and restrict post-closing contact to limited status verification. Records are not sold or made public, authorizations are revocable if you withdraw, and the issuing insurance carrier does not receive the life expectancy reports.

What happens if my health changes after the life expectancy report is issued?

Reports have a practical shelf life of roughly a year, and material health changes can shorten it. If your condition worsens significantly before closing, updated records can justify refreshed underwriting and potentially higher bids; if the process stalls for many months, buyers may require new reports before honoring or renewing offers. After closing, health changes are irrelevant to you financially — the buyer bears all longevity risk from that point, which is exactly the risk they were compensated for in pricing.

Can I get my own life expectancy report before deciding whether to sell?

Some underwriting firms accept consumer or advisor-initiated orders, and a preliminary estimate can help you gauge marketability before committing to the full process. Be aware of two caveats: buyers will still order their own independent reports and will not price off yours, and a self-ordered report costs money that may be wasted if the policy is clearly marketable anyway. A lighter-weight first step is a qualification review of age (generally 65+), face value (generally $100,000+), policy type, and premium level.

Related Reading

• Independent Life Expectancy Reports
• Life Settlement Pricing Mechanics
• How Do Life Settlements Work
• Who Qualifies For A Life Settlement
• How Life Settlement Value Is Calculated

---

Pine Lake Life Solutions does not purchase life insurance policies and does not provide legal, tax, or investment advice. Information provided is for educational purposes only. Eligibility for any option, including life settlements, is not guaranteed and depends on individual circumstances, policy terms, underwriting, and market conditions. Consult independent legal, tax, or financial professionals before making decisions regarding a life insurance policy.